May 4, 2015 - The lead plaintiff filed a notice of appeal.
April 3, 2015 - The court granted the defendants' motion to dismiss and ordered the case closed.

December 12, 2014 - The defendants filed a motion to dismiss.

October 30, 2014 - The lead plaintiff filed a complaint.

October 7, 2014 - The lead plaintiff and lead counsel were appointed.

October 3, 2014 - Lead plaintiff motions were filed.

July 31, 2014 - An investor in shares of Invivo Therapeutics Holdings Corp (OTC: NVIV) filed a lawsuit in the U.S. District Court for the District of Massachusetts against Invivo Therapeutics Holdings Corp over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between April 5, 2013 and August 26, 2013.

According to the complaint the plaintiff alleges on behalf of purchasers of Invivo Therapeutics Holdings Corp (OTC: NVIV) common shares between April 5, 2013 and August 26, 2013, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that the defendants made allegedly false and misleading statements about the FDA's approval of a clinical trial and the time for completion of the trial and submission of data to the FDA.

Shares of Invivo Therapeutics Holdings Corp (OTC: NVIV) grew from $1.37 per share in October 2012 to as high as $5.49 per share in July 2013.

Then on August 27, 2013, Invivo Therapeutics Holdings Corp announced an update on the clinical timeline for its biopolymer scaffolding to treat acute SCI.

Shares of Invivo Therapeutics Holdings Corp (OTC: NVIV) declined from $4.11 on August 20, 2014, to $1.19 per share on August 30, 2013.

Invivo Therapeutics Holdings Corp reported that its Net Income of $4.66 million in 2012 declined to a Net Loss of $38.76 million in 2013.

On August 8, 2014, OTC: NVIV shares closed $0.815 per share.